Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

2(22%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_1

22%

Ph phase_4

44%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

2(22.2%)

Phase 2Efficacy & side effects

3(33.3%)

Phase 4Post-market surveillance

4(44.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Other(4)

Detailed Status

unknown4

Completed3

Active, not recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (22.2%)

Phase 23 (33.3%)

Phase 44 (44.4%)

Trials by Status

unknown444%

active_not_recruiting111%

completed333%

recruiting111%

Recent Activity

2 active trials

Showing 5 of 9

recruitingphase_1

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

NCT05719714

completedphase_2

Dapagliflozin in Pulmonary Arterial Hypertension

NCT05179356

completedphase_4

Dapagliflozin Treatment in Type 2 Diabetes

NCT04620590

active_not_recruitingphase_2

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

NCT06111443

completedphase_1

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

NCT04545411

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT05719714Phase 1

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Recruiting

NCT05179356Phase 2

Dapagliflozin in Pulmonary Arterial Hypertension

Completed

NCT04620590Phase 4

Dapagliflozin Treatment in Type 2 Diabetes

Completed

NCT06111443Phase 2

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Active Not Recruiting

NCT04545411Phase 1

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Completed

NCT05250752Phase 2

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment

Unknown

NCT05225077Phase 4

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Unknown

NCT04739215Phase 4

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

Unknown

NCT03398577Phase 4

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Unknown

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9